UK NAO Cancer Drug Fund Probe Curbed By Data Gaps
This article was originally published in Scrip
England's Cancer Drug Fund (CDF) seems to have contributed to the use of innovative drugs in the UK but its actual impact on patient outcomes is unclear, due to lack of evidence, according to a study by Britain's National Audit Office (NAO).
You may also be interested in...
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.
Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.